Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Blyth, S. Chen, M. Slavin, Carole Serena, Quoc Nguyen, D. Marriott, D. Ellis, W. Meyer, T. Sorrell (2009)
Not Just Little Adults: Candidemia Epidemiology, Molecular Characterization, and Antifungal Susceptibility in Neonatal and Pediatric PatientsPediatrics, 123
P. Pappas, C. Kauffman, D. Andes, C. Clancy, K. Marr, L. Ostrosky-Zeichner, A. Reboli, M. Schuster, J. Vázquez, T. Walsh, T. Zaoutis, J. Sobel (2016)
Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 62 4
C. Pfeiffer, G. García-Effrón, A. Zaas, J. Perfect, D. Perlin, B. Alexander (2010)
Breakthrough Invasive Candidiasis in Patients on MicafunginJournal of Clinical Microbiology, 48
M. Science, P. Robinson, Tamara MacDonald, S. Rassekh, L. Dupuis, L. Sung (2014)
Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipientsPediatric Blood & Cancer, 61
Pappas (2016)
Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America.Clin Infect Dis, 62
B. Fisher, T. Zaoutis, C. Dvorak, M. Nieder, D. Zerr, J. Wingard, C. Callahan, D. Villaluna, Lu Chen, H. Dang, A. Esbenshade, S. Alexander, J. Wiley, L. Sung (2019)
Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial.JAMA, 322 17
M. Pfaller, D. Diekema, J. Turnidge, M. Castanheira, Ronald Jones (2019)
Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016Open Forum Infectious Diseases, 6
Letters employed by the funding institution who are included as authors or in the participants diagnosed at 65 years or older. There was no acknowledgments. trend by age for PV prevalence in BRCA1/2 (P = .34) or other Meeting Presentation: Preliminary results were presented in partial form at breast cancer–associated genes (P =.54) (Table 2). the American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, June 2019. Discussion | In this study, 3.55% of unselected, postmeno- Additional Contributions: We thank Krystal Brown, PhD, Maria Elias, PhD, pausal patients with breast cancer carried PVs in breast Anne-Renee Hartman, MD, (currently employed by GRAIL Inc), Elisha Hughes, PhD, Jonathan Lancaster, MD, PhD, Eric Rosenthal, PhD, ScM, and Nanda Singh, cancer–associated genes, a 3-fold higher prevalence than PhD, Myriad Genetics; Kathy Pan, MD, Los Angeles Biomedical Institute at among cancer-free control participants and without decrease Harbor-UCLA; Lihong Qi, PhD, University of California, Davis; Kerryn Reding, by age. Women diagnosed when younger than 65 years had PhD, Fred Hutchinson Cancer Research Center and University of Washington; similar probability of BRCA1/2 PVs as Ashkenazi Jewish indi- and Jean Tang, MD, PhD, Stanford University; for their assistance in assay performance and analysis, preparation, and critical
JAMA – American Medical Association
Published: Mar 10, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.